No Data
Express News | Nuvation Bio Announces Updates and Upcoming Presentations for Its Ros1 Inhibitor, Taletrectinib
BTIG Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $5
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Nuvation Bio Amid Promising Taletrectinib Trials and Orphan Drug Designation
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth
Jaguar8 : Wow 2 straight days of buying if I remember
TrytosaveabitOP : A little over 2 million worth in 5 days or so! WooHoo! Hehehe
Jaguar8 TrytosaveabitOP: Well with its promising 91% tumor reduction in NSCLC study, he is confident about it. 91% is a wow
TrytosaveabitOP Jaguar8: Oh yeah! You know I’m in total agreement with you here!
Jaguar8 TrytosaveabitOP: And we should be confident about it too with his loading
View more comments...